Dominique Hubert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/499742/publications.pdf

Version: 2024-02-01

623574 839398 18 741 14 18 citations g-index h-index papers 19 19 19 802 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	2.5	139
2	Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	2.5	95
3	Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. Journal of Cystic Fibrosis, 2017, 16, 388-391.	0.3	81
4	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212.	0.3	76
5	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	1.1	53
6	Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 114-121.	5.5	53
7	Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting. Journal of Cystic Fibrosis, 2018, 17, 89-95.	0.3	51
8	Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatric Pulmonology, 2017, 52, 190-197.	1.0	33
9	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. European Respiratory Journal, 2016, 48, 249-252.	3.1	30
10	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.3	24
11	Maternal and perinatal outcomes of pregnancies in women with cystic fibrosis – A single centre case-control study. Respiratory Medicine, 2016, 113, 22-27.	1.3	22
12	Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases. PLoS ONE, 2017, 12, e0187930.	1.1	21
13	Pregnancy after lung and heart–lung transplantation: a French multicentre retrospective study of 39 pregnancies. ERJ Open Research, 2019, 5, 00254-2018.	1.1	17
14	Management of assisted reproductive technologies in women with cystic fibrosis. Fertility and Sterility, 2001, 76, 1280-1281.	0.5	15
15	Discussion on genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology, 2003, 125, 1286.	0.6	13
16	Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. Pulmonary Therapy, 2021, 7, 455-468.	1.1	8
17	CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. Pancreatology, 2016, 16, 515-522.	0.5	6
18	A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2018, 17, 636-642.	0.3	4